Implementation of Nucleic Acid Amplification Testing Screening to Identify Acute and Early HIV Infection
Status
Conditions
Treatments
Details and patient eligibility
About
The investigators propose to study the impact of nucleic acid amplification testing (NAT) screening for acute Human Immunodeficiency Virus (HIV) and Hepatitis C (HCV) infections and Less-Sensitive Enzyme linked Immunoassay (LS-EIA) or 'detuned' testing Vironostika, Trinity Biotech BED, or Ortho-Clinical Diagnostic Vistros ECi for early HIV infection in conjunction with routine rapid HIV testing at HIV counseling and testing sites and venues in the San Diego county. The overarching goal of this study is to develop and implement a system to identify, notify and engage into care those individuals with recent HIV infection in order to better define the HIV and Hepatitis C Virus (HCV) epidemics in the San Diego county and to evaluate and characterize HIV transmission dynamics within the San Diego population.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Persons presenting for HIV testing to Public Health Department HIV testing site.
- Men and women >13 years of age.
- Those who are 13 or older and younger than 18 should be an emancipated minor or have consent given by their legal representative.
- Participants 18 and over must be able to provide written consent.
- Participants should be available for follow up for a period of at least 2 weeks after enrollment
Exclusion criteria
- Refusal to participate.
- Unable to provide informed consent.
Trial design
Primary purpose
Allocation
Interventional model
Masking
22,607 participants in 1 patient group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal